Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM, Noronha V, Joshi A, Dhumal S, Mahimkar M, Bhattacharjee A, Gota V, Pandey M, Menon N, Mahajan A, Sable N, Kumar S, Nawale K, Mukadam S, Solanki B, Das S, Simha V, Abraham G, Chandrasekharan A, Talreja V, DSouza H, Srinivas S, Kashyap L, Banavali S, Prabhash K. Patil VM, et al. Among authors: dsouza h. J Clin Oncol. 2019 Nov 10;37(32):3032-3041. doi: 10.1200/JCO.19.01076. Epub 2019 Sep 20. J Clin Oncol. 2019. PMID: 31539316 Clinical Trial.
Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
Joshi A, Patil V, Noronha V, Dhumal S, Pande N, Chandrasekharan A, Turkar S, DSouza H, Shrirangwar S, Mahajan A, Arya S, Juvekar S, BhattaCharjee A, Prabhash K. Joshi A, et al. Among authors: dsouza h. Oral Oncol. 2017 Dec;75:54-60. doi: 10.1016/j.oraloncology.2017.10.018. Epub 2017 Nov 5. Oral Oncol. 2017. PMID: 29224823 Clinical Trial.
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil V, et al. Among authors: dsouza h. EClinicalMedicine. 2019 Apr 9;9:19-25. doi: 10.1016/j.eclinm.2019.03.011. eCollection 2019 Mar. EClinicalMedicine. 2019. PMID: 31143878 Free PMC article.
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K. Patil VM, et al. Among authors: dsouza h. Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31. Cancer. 2019. PMID: 31150120 Free article. Clinical Trial.
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.
Noronha V, Patil VM, Joshi A, Mahimkar M, Patel U, Pandey MK, Chandrasekharan A, Dsouza H, Bhattacharjee A, Mahajan A, Sabale N, Agarwal JP, Ghosh-Laskar S, Budrukkar A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Nair S, Thiagarajan S, Banavali S, Prabhash K. Noronha V, et al. Among authors: dsouza h. Oncotarget. 2020 Jan 28;11(4):399-408. doi: 10.18632/oncotarget.27443. eCollection 2020 Jan 28. Oncotarget. 2020. PMID: 32064043 Free PMC article.
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V, Noronha V, Dhumal SB, Joshi A, Menon N, Bhattacharjee A, Kulkarni S, Ankathi SK, Mahajan A, Sable N, Nawale K, Bhelekar A, Mukadam S, Chandrasekharan A, Das S, Vallathol D, D'Souza H, Kumar A, Agrawal A, Khaddar S, Rathnasamy N, Shenoy R, Kashyap L, Rai RK, Abraham G, Saha S, Majumdar S, Karuvandan N, Simha V, Babu V, Elamarthi P, Rajpurohit A, Kumar KAP, Srikanth A, Ravind R, Banavali S, Prabhash K. Patil V, et al. Lancet Glob Health. 2020 Sep;8(9):e1213-e1222. doi: 10.1016/S2214-109X(20)30275-8. Lancet Glob Health. 2020. PMID: 32827483 Free article. Clinical Trial.
Thromboembolic events in brain tumour patients on bevacizumab.
Singh GK, Menon N, Jadhav MM, Walavalkar R, DSouza H, Roy S, Das S, Srinivas S, Vallathol DH, Patil VM. Singh GK, et al. Among authors: dsouza h. Acta Oncol. 2020 Dec;59(12):1543-1546. doi: 10.1080/0284186X.2020.1815834. Epub 2020 Sep 8. Acta Oncol. 2020. PMID: 32897111 No abstract available.
Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma.
Kumar G, DSouza H, Menon N, Srinivas S, Vallathol DH, Boppana M, Rajpurohit A, Mahajan A, Janu A, Chatterjee A, Krishnatry R, Gupta T, Jalali R, Patil VM. Kumar G, et al. Among authors: dsouza h. Ecancermedicalscience. 2021 Jan 13;15:1166. doi: 10.3332/ecancer.2021.1166. eCollection 2021. Ecancermedicalscience. 2021. PMID: 33680080 Free PMC article.
Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
Patil VM, Noronha V, Joshi A, Kumar A, Dsouza H, Bhattacharjee A, Mahajan A, Sabale N, Ghosh-Laskar S, Prabhash K. Patil VM, et al. Among authors: dsouza h. South Asian J Cancer. 2020 Oct;9(4):195-198. doi: 10.1055/s-0041-1728225. Epub 2021 Jun 12. South Asian J Cancer. 2020. PMID: 34131571 Free PMC article.
132 results